Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
3(30%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_1
4
40%
Ph phase_2
4
40%
Ph phase_3
1
10%

Phase Distribution

4

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

10

all time

Status Distribution
Active(4)
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Recruiting2
Withdrawn2
Active, not recruiting1
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (44.4%)
Phase 24 (44.4%)
Phase 31 (11.1%)

Trials by Status

active_not_recruiting110%
completed330%
not_yet_recruiting110%
recruiting220%
unknown110%
withdrawn220%

Recent Activity

3 active trials
Showing 5 of 10
not_yet_recruitingphase_2

Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms

NCT07549451
recruitingphase_1

Imetelstat Combinations in Relapsed AML

NCT07320235
recruitingphase_1

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

NCT06247787
active_not_recruitingphase_3

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

NCT04576156
unknown

Expanded Access for Treatment With Imetelstat

NCT05937568
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07549451Phase 2

Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms

Not Yet Recruiting
NCT07320235Phase 1

Imetelstat Combinations in Relapsed AML

Recruiting
NCT06247787Phase 1

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recruiting
NCT04576156Phase 3

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Active Not Recruiting
NCT05937568

Expanded Access for Treatment With Imetelstat

Unknown
NCT01731951Phase 2

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Completed
NCT01916187Phase 1

Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma

Withdrawn
NCT01137968Phase 2

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

Completed
NCT01243073Phase 2

Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera

Completed
NCT01568632Phase 1

Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma

Withdrawn

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10